These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Clayton EL; Mizielinska S; Edgar JR; Nielsen TT; Marshall S; Norona FE; Robbins M; Damirji H; Holm IE; Johannsen P; Nielsen JE; Asante EA; Collinge J; ; Isaacs AM Acta Neuropathol; 2015 Oct; 130(4):511-23. PubMed ID: 26358247 [TBL] [Abstract][Full Text] [Related]
9. Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation. Clayton EL; Mancuso R; Nielsen TT; Mizielinska S; Holmes H; Powell N; Norona F; Larsen JO; Milioto C; Wilson KM; Lythgoe MF; Ourselin S; Nielsen JE; Johannsen P; Holm I; Collinge J; ; Oliver PL; Gomez-Nicola D; Isaacs AM Hum Mol Genet; 2017 Mar; 26(5):873-887. PubMed ID: 28093491 [TBL] [Abstract][Full Text] [Related]
10. The role of CHMP2B Krasniak CS; Ahmad ST Brain Res; 2016 Oct; 1649(Pt B):151-157. PubMed ID: 26972529 [TBL] [Abstract][Full Text] [Related]
11. Lessons learned from CHMP2B, implications for frontotemporal dementia and amyotrophic lateral sclerosis. Ugbode C; West RJH Neurobiol Dis; 2021 Jan; 147():105144. PubMed ID: 33144171 [TBL] [Abstract][Full Text] [Related]
12. A novel splice-site mutation in CHMP2B associated with frontotemporal dementia: The first report from China and literature review. Li C; Wen Y; Zhao M; Wang Y; Li P; Wang L; Wang S Mol Genet Genomic Med; 2023 Aug; 11(8):e2222. PubMed ID: 37272767 [TBL] [Abstract][Full Text] [Related]
13. TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD-3-linked CHMP2B, a complex of ESCRT-III. Jun MH; Han JH; Lee YK; Jang DJ; Kaang BK; Lee JA Mol Brain; 2015 Dec; 8():85. PubMed ID: 26651479 [TBL] [Abstract][Full Text] [Related]
14. Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective study. Stokholm J; Teasdale TW; Johannsen P; Nielsen JE; Nielsen TT; Isaacs A; Brown JM; Gade A; J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):170-6. PubMed ID: 23142962 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective activity of ursodeoxycholic acid in CHMP2B West RJH; Ugbode C; Fort-Aznar L; Sweeney ST Neurobiol Dis; 2020 Oct; 144():105047. PubMed ID: 32801000 [TBL] [Abstract][Full Text] [Related]
16. Longitudinal transcriptomic analysis of altered pathways in a CHMP2B Waegaert R; Dirrig-Grosch S; Parisot F; Keime C; Henriques A; Loeffler JP; René F Neurobiol Dis; 2020 Mar; 136():104710. PubMed ID: 31837425 [TBL] [Abstract][Full Text] [Related]
17. Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Urwin H; Authier A; Nielsen JE; Metcalf D; Powell C; Froud K; Malcolm DS; Holm I; Johannsen P; Brown J; Fisher EM; van der Zee J; Bruyland M; ; Van Broeckhoven C; Collinge J; Brandner S; Futter C; Isaacs AM Hum Mol Genet; 2010 Jun; 19(11):2228-38. PubMed ID: 20223751 [TBL] [Abstract][Full Text] [Related]
18. Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Holm IE; Isaacs AM; Mackenzie IR Acta Neuropathol; 2009 Nov; 118(5):719-20. PubMed ID: 19844732 [No Abstract] [Full Text] [Related]
19. Alteration of microglial metabolism and inflammatory profile contributes to neurotoxicity in a hiPSC-derived microglia model of frontotemporal dementia 3. Haukedal H; Syshøj Lorenzen S; Winther Westi E; Corsi GI; Gadekar VP; McQuade A; Davtyan H; Doncheva NT; Schmid B; Chandrasekaran A; Seemann SE; Cirera S; Blurton-Jones M; Meyer M; Gorodkin J; Aldana BI; Freude K Brain Behav Immun; 2023 Oct; 113():353-373. PubMed ID: 37543250 [TBL] [Abstract][Full Text] [Related]
20. Molecular Genetics of Frontotemporal Dementia Elucidated by Vandal SE; Zheng X; Ahmad ST Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]